Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes... Show more
Industry PharmaceuticalsOther
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| ADX.X | 0.064154 | 0.001306 | +2.08% |
| heyAura cryptocurrency | |||
| RLC.X | 0.361863 | 0.004074 | +1.14% |
| iExec RLC cryptocurrency | |||
| DAI.X | 0.999896 | 0.000286 | +0.03% |
| Dai cryptocurrency | |||
| RSR.X | 0.001679 | -0.000022 | -1.32% |
| Reserve Rights cryptocurrency | |||
| LOOM.X | 0.000172 | -0.000041 | -19.23% |
| Loom Network cryptocurrency | |||
A.I.dvisor indicates that over the last year, EMBC has been loosely correlated with BLFS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if EMBC jumps, then BLFS could also see price increases.
| Ticker / NAME | Correlation To EMBC | 1D Price Change % | ||
|---|---|---|---|---|
| EMBC | 100% | +2.30% | ||
| BLFS - EMBC | 43% Loosely correlated | -5.33% | ||
| WAT - EMBC | 37% Loosely correlated | -3.15% | ||
| MTD - EMBC | 37% Loosely correlated | -1.97% | ||
| AVTR - EMBC | 37% Loosely correlated | -0.13% | ||
| RVTY - EMBC | 36% Loosely correlated | -2.51% | ||
More | ||||
| Ticker / NAME | Correlation To EMBC | 1D Price Change % |
|---|---|---|
| EMBC | 100% | +2.30% |
| Pharmaceuticals: Other industry (50 stocks) | 19% Poorly correlated | -0.52% |
| Pharmaceuticals industry (154 stocks) | 1% Poorly correlated | -0.74% |
EMBC's Aroon Indicator triggered a bullish signal on October 01, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 139 similar instances where the Aroon Indicator showed a similar pattern. In 109 of the 139 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 78%.
The Momentum Indicator moved above the 0 level on September 22, 2026. You may want to consider a long position or call options on EMBC as a result. In 58 of 77 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for EMBC just turned positive on September 25, 2026. Looking at past instances where EMBC's MACD turned positive, the stock continued to rise in 27 of 39 cases over the following month. The odds of a continued upward trend are 69%.
Following a +5.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMBC advanced for three days, in 179 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The 10-day RSI Indicator for EMBC moved out of overbought territory on September 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 22 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMBC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
EMBC broke above its upper Bollinger Band on September 25, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 1 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.614) is normal, around the industry mean (5.011). P/E Ratio (4.041) is within average values for comparable stocks, (163.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.456). EMBC's Dividend Yield (0.054) is considerably higher than the industry average of (0.005). P/S Ratio (0.300) is also within normal values, averaging (56.074).
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. EMBC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EMBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.